Breaking News Instant updates and real-time market news.

MDT

Medtronic

$81.88

-1.645 (-1.97%)

, DXCM

Dexcom

$73.06

-0.14 (-0.19%)

10:34
08/22/17
08/22
10:34
08/22/17
10:34

Medtronic challenges in diabetes good news for Dexcom, Tandem, says JPMorgan

JPMorgan analyst Michael Weinstein noted that Medtronic (MDT) guided for its diabetes revenues to be down sequentially in the second and third quarters and lowered its diabetes growth guidance for the year. He said Medtronic's challenges "are naturally competitors' gains," and tells investors that he expects Dexcom (DXCM) and Tandem Diabetes (TNDM) to respond favorably to the news. Weinstein has an Overweight rating on Dexcom shares.

MDT

Medtronic

$81.88

-1.645 (-1.97%)

DXCM

Dexcom

$73.06

-0.14 (-0.19%)

TNDM

TNDM

  • 22

    Aug

  • 22

    Aug

  • 06

    Sep

  • 07

    Sep

  • 20

    Sep

MDT Medtronic
$81.88

-1.645 (-1.97%)

08/22/17
COWN
08/22/17
NO CHANGE
Target $95
COWN
Outperform
Medtronic positioned to bounce off of Q1 slowdown, says Cowen
Cowen analyst Joshua Jennings noted Medtronic's recent top-line momentum was thwarted by an IT problem and capacity constraint in Diabetes, but he believes organic revenue growth should rebound to the roughly 4% range. He cited soft comps and a tailwind from the Supplies divestiture. Jennings reiterated his Outperform rating and $95 price target on Medtronic shares.
07/06/17
07/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nike (NKE) initiated with an Outperform at Raymond James. 2. JPMorgan (JPM) initiated with a Neutral at Goldman Sachs. 3. At Home Group (HOME) initiated with a Buy at SunTrust. 4. Logitech (LOGI) initiated with a Buy at Citi. 5. Medtronic (MDT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
DBAB
07/31/17
NO CHANGE
Target $96
DBAB
Buy
Medtronic attractive following share underperformance, says Deutsche Bank
Deutsche Bank analyst Brittany Henderson believes Medtronic shares represent an attractive investment opportunity after underperforming the broader S&P 500 medical supplies and devices index over the last 12 months. The company is well positioned for the "changing dynamics of the global healthcare environment," Henderson tells investors in a research note tilted "It is Time to Appreciate the Margin Expansion Story; Buy." She views the company as a mid-single digit sales and double digit earnings grower. The analyst reiterates a Buy rating on Medtronic with a $96 price target.
08/16/17
PIPR
08/16/17
NO CHANGE
Target $87
PIPR
Overweight
Piper calls Dexcom fears overblown, ups price target to $87
After analyzing the impact of Abbott's (ABT) FreeStyle Libre approval and Medtronic's (MDT) 670G rollout, Piper Jaffray analyst Matt O'Brien believes competitive fears for Dexcom (DXCM) are overblown. The ultimate impact on Dexcom from these technologies "will be less than feared" as FreeStlye Libre is unlikely to get a non-adjunctive claim and the 670G roll out will be slower than expected, O'Brien tells investors in a research note. He expects this to drive multiple expansion for Dexcom shares. The analyst upped his price target for the stock to $87 from $78 and keeps an Overweight rating on the name.
DXCM Dexcom
$73.06

-0.14 (-0.19%)

08/02/17
SPHN
08/02/17
NO CHANGE
Target $83
SPHN
Overweight
Dexcom price target lowered to $83 from $95 at Stephens
Stephens analyst Chris Cooley lowered his price target for Dexcom to $83 from $95 after the company reported Q2 operating results. The analyst reiterates an Overweight rating on the shares.
07/13/17
BTIG
07/13/17
NO CHANGE
BTIG
Buy
Abbott, Bigfoot deal a 'major validation' for both, says BTIG
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
08/02/17
OPCO
08/02/17
NO CHANGE
Target $92
OPCO
Outperform
Dexcom price target lowered to $92 from $98 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom to $92 from $98 on reduced sales offset by recent peer multiple appreciation. The analyst reiterates an Outperform rating on the shares.
TNDM TNDM

11/03/16
PIPR
11/03/16
DOWNGRADE
Target $2.5
PIPR
Neutral
Tandem Diabetes downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Brooks West downgraded Tandem Diabetes (TNDM) to Neutral with a $2.50 price target following the Q3 miss citing low visibility and increased competitive headwinds from Medtronic's (MDT) 630G/670G launch.
03/24/17
RILY
03/24/17
DOWNGRADE
Target $1.5
RILY
Neutral
Tandem Diabetes downgraded to Neutral from Buy at B. Riley
B. Riley analyst Greg Chodaczek downgraded Tandem Diabetes to Neutral citing a weakening balance sheet. The "weak" equity offering shows a lack of institutional investor demand, the analyst contends. He cut his price target for the shares to $1.50 from $5.
03/30/17
PIPR
03/30/17
INITIATION
Target $1.5
PIPR
Neutral
Tandem Diabetes assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Matt O'Brien assumed coverage of Tandem Diabetes with a Neutral rating and $1.50 price target.
04/10/17
COWN
04/10/17
DOWNGRADE
COWN
Market Perform
Tandem Diabetes downgraded to Market Perform from Outperform at Cowen

TODAY'S FREE FLY STORIES

10:31
09/20/17
09/20
10:31
09/20/17
10:31
General news
Crude inventories for week of September 15 »

Crude oil inventories…

PYPL

PayPal

$63.83

0.91 (1.45%)

10:30
09/20/17
09/20
10:30
09/20/17
10:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 22

    Oct

  • 29

    Nov

10:30
09/20/17
09/20
10:30
09/20/17
10:30
General news
The 1.7% U.S. August existing home sales drop »

The 1.7% U.S. August…

AAXN

Axon

$22.07

-0.33 (-1.47%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Periodicals
Studies about Taser's safety were overstated, Reuters reports »

Claims about early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$317.93

-0.25 (-0.08%)

, CBAY

CymaBay

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BIIB

Biogen

$317.93

-0.25 (-0.08%)

CBAY

CymaBay

EVH

Evolent Health

$16.18

0.5299 (3.39%)

EPZM

Epizyme

$19.25

1.4 (7.84%)

INTU

Intuit

$145.34

1.54 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 03

    Oct

  • 22

    Oct

  • 25

    Oct

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

, UAL

United Continental

$58.01

0.47 (0.82%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

UAL

United Continental

$58.01

0.47 (0.82%)

IR

Ingersoll-Rand

$88.85

-1.61 (-1.78%)

LB

L Brands

$37.40

-1.83 (-4.66%)

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 17

    Oct

PFE

Pfizer

$35.91

0.455 (1.28%)

, PGR

Progressive

$47.57

-0.065 (-0.14%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

PFE

Pfizer

$35.91

0.455 (1.28%)

PGR

Progressive

$47.57

-0.065 (-0.14%)

AAL

American Airlines

$44.38

-0.93 (-2.05%)

LUV

Southwest

$53.77

0.23 (0.43%)

POST

Post Holdings

$86.68

0.32 (0.37%)

NDSN

Nordson

$114.62

0.12 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 18

    Oct

  • 31

    Oct

CELC

Celcuity

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Syndicate
Celcuity opens at $12.35, IPO priced at $9.50 per share »

Celcuity (CELC) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WDC

Western Digital

$89.92

0.74 (0.83%)

, TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

10:28
09/20/17
09/20
10:28
09/20/17
10:28
Recommendations
Western Digital, Toshiba, also use TOSYY analyst commentary  »

Western Digital…

WDC

Western Digital

$89.92

0.74 (0.83%)

TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$81.07

-0.12 (-0.15%)

10:25
09/20/17
09/20
10:25
09/20/17
10:25
Conference/Events
Medtronic has conference call hosted by Leerink »

Leerink to hold a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

PPC

Pilgrim's Pride

$28.91

-0.63 (-2.13%)

10:25
09/20/17
09/20
10:25
09/20/17
10:25
Conference/Events
Pilgrim's Pride holds an investor day »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

DESP

Despegar.com

10:21
09/20/17
09/20
10:21
09/20/17
10:21
Syndicate
Breaking Syndicate news story on Despegar.com »

Despegar.com opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AAPL

Apple

$158.73

0.06 (0.04%)

10:20
09/20/17
09/20
10:20
09/20/17
10:20
Options
Heavy trading in Apple as shares come under fire Wednesday »

Heavy trading in Apple as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 22

    Oct

10:20
09/20/17
09/20
10:20
09/20/17
10:20
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

CVX

Chevron

$116.75

0.405 (0.35%)

10:19
09/20/17
09/20
10:19
09/20/17
10:19
Periodicals
Chevron drills well in Iraqi Kurdish area after two-year interlude, Reuters says »

Despite an international…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 09

    Nov

DESP

Despegar.com

10:19
09/20/17
09/20
10:19
09/20/17
10:19
Syndicate
Breaking Syndicate news story on Despegar.com »

Despegar.com IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

$NSD

NASDAQ Market Internals

10:17
09/20/17
09/20
10:17
09/20/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
09/20/17
09/20
10:16
09/20/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFFN

Diffusion Pharmaceuticals

$1.75

-0.01 (-0.57%)

10:16
09/20/17
09/20
10:16
09/20/17
10:16
Hot Stocks
Diffusion Pharmaceuticals granted European patent for bipolar trans carotenoids 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
09/20/17
09/20
10:15
09/20/17
10:15
General news
U.S. existing home sales dropped 1.7% to 5.35 M in August »

U.S. existing home sales…

10:15
09/20/17
09/20
10:15
09/20/17
10:15
General news
Breaking General news story  »

Week of 9/15 EIA…

KR

Kroger

$20.87

-0.26 (-1.23%)

10:10
09/20/17
09/20
10:10
09/20/17
10:10
Options
Put buyers in Kroger as shares slip »

Put buyers in Kroger as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

10:10
09/20/17
09/20
10:10
09/20/17
10:10
General news
FX Action: The dollar »

FX Action: The dollar was…

IONS

Ionis Pharmaceuticals

$59.07

-0.5 (-0.84%)

, BIIB

Biogen

$317.93

-0.25 (-0.08%)

10:06
09/20/17
09/20
10:06
09/20/17
10:06
Recommendations
Ionis Pharmaceuticals, Biogen, Alnylam analyst commentary  »

Ionis story still about…

IONS

Ionis Pharmaceuticals

$59.07

-0.5 (-0.84%)

BIIB

Biogen

$317.93

-0.25 (-0.08%)

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GIS

General Mills

$52.24

-3.14 (-5.67%)

10:05
09/20/17
09/20
10:05
09/20/17
10:05
Technical Analysis
Technical View: General Mills falls after results and outlook »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.